[1]金世龙,黄中荣,陈华,等.HuH7细胞系CD13+CD133+HCC细胞分选及CSCs特性分析[J].陆军军医大学学报(原第三军医大学学报),2012,34(16):1658-1662.
 Jin Shilong,Huang Zhongrong,Chen Hua,et al.Sorting and cancer stem cell characteristic analysis of CD13+CD133+HCC cells in HuH7 cell line[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(16):1658-1662.
点击复制

HuH7细胞系CD13+CD133+HCC细胞分选及CSCs特性分析(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第16期
页码:
1658-1662
栏目:
论著
出版日期:
2012-08-30

文章信息/Info

Title:
Sorting and cancer stem cell characteristic analysis of CD13+CD133+HCC cells in HuH7 cell line
作者:
金世龙黄中荣陈华余天雾曹洪龙运全周健李鹤苟毅廖娟
重庆医科大学附属永川医院肝胆外科
Author(s):
Jin Shilong Huang Zhongrong Chen Hua Yu Tianwu Cao Hong Long Yunquan Zhou Jian Li He Gou Yi Liao Juan
Department of Hepatiobiliary Surgery, Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160, China
关键词:
肝癌癌干细胞CD13 CD133
Keywords:
liver cancer cancer stem cells CD13 CD133
分类号:
R329-33;R730.23;R735.7
文献标志码:
A
摘要:
目的      探讨CD13、CD133双荧光标志流式细胞术(fluorescence activated cell sorter,FACS)分选人肝癌HuH7细胞系CD13+CD133+HCC细胞方法及癌干细胞(cancer stem cells,CSCs)特征。      方法      CD13、CD133双标志,采用FACS从人肝癌HuH7细胞系分选出CD13+CD133+HCC、CD13+CD133-HCC、CD13-CD133+HCC、CD13-CD133-HCC等4种细胞亚群;通过CD13+CD133+HCC细胞生长曲线,细胞周期,形成肿瘤球和裸鼠体内成瘤能力,及对5-FU、吡柔比星化疗药物的敏感性研究,分析CD13+CD133+HCC细胞是否具有CSCs生物学特征。      结果      人肝癌HuH7细胞系CD13+CD133+HCC细胞占23.8%, 3.1%分选为CD13+CD133+HCC细胞,78.45%的CD13+CD133+HCC细胞处于G0/G1期;CD13+CD133+HCC细胞增殖明显快于其他3个细胞亚群;在裸鼠103个CD13+CD133+HCC细胞就可以成瘤,而1.0×105个CD13-CD133-HCC只有2只成瘤(2/5),干细胞培养CD13+CD133+HCC细胞8~15 d形成肿瘤球;CD13+CD133+HCC细胞对5-FU和吡柔比星具有抵抗特性,而其他3个亚群较易于杀灭。      结论      CD13、CD133双标志FACS从HuH7分选的CD13+CD133+HCC细胞具有CSCs特征,可能成为HCC治疗靶细胞。
Abstract:
Objective      To study the sorting of CD13+CD133+HCC cell fraction in HuH7 cell line by fluorescence activated cell sorter (FACS) based on the expression of both CD13 and CD133 markers, and to analyze the cancer stem cells (CSCs) characteristics of CD13+CD133+HCC cells.       Methods      The antibodies against CD13 and CD133 were used as CSCs marker to sort CD13+CD133+HCC cells, CD13+CD133-HCC cells, CD13-CD133+HCC cells and CD13-CD133-HCC cells from HuH7 cell line by FACS. The growth curve, phase of cell cycle, sphere formation ability in vitro, tumor formation ability in vivo and susceptibility to 5-FU and pirarubicin of the CD13+CD133+HCC cells were investigated for CSCs identification and characterization of the CD13+CD133+HCC cells.       Results      The CD13+CD133+HCC cells accounted for 23.8% in HuH7 cell line, and 3.1% of the CD13+CD133+HCC cells was sorted as CSC-like cells. There was 78.45% of the CD13+CD133+HCC cells existed in G1/G0 phase. The proliferating ability of the CD13+CD133+HCC cells was significantly stronger than that of the other cell subsets. The CD13+CD133+HCC cells could form a tumor in naked mice after 4 weeks with a number of 103, but 1.0×105 of the CD13-CD133-HCC cells were needed to form a tumor. The in vitro sphere formation of the CD13+CD133+HCC cells was observed after 8 to 15 d. The CD13+CD133+HCC cells had the chemo-resistant ability to 5-FU and pirarubicin, but the other cell subsets could be killed easily by these drugs.       Conclusion      The CD13+CD133+HCC cells sorted from HuH7 cell line by FACS based on the expression of both CD13 and CD133 markers have the characteristics of CSCs, and may be the therapeutic target for human hepatocellular carcinoma.

相似文献/References:

[1]庞林宾,王洪林,王晔飞,等.JAK2/STAT3通路在肝癌细胞侵袭及血管生成拟态中的作用[J].陆军军医大学学报(原第三军医大学学报),2012,34(18):1862.
 Pang Linbin,Wang Honglin,Wang Yefei,et al.Role JAK2/STAT3 signaling pathway in invasion and vascular mimicry of liver cancer cells[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(16):1862.
[2]熊震,汤旭东,房殿春,等.人肝素酶RNAi序列的筛选及鉴定[J].陆军军医大学学报(原第三军医大学学报),2007,29(20):1929.
 XIONG Zhen,TANG Xu-dong,FANG Dian-chun,et al.Screening and identification of heparanase RNAi sequence[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(16):1929.
[3]向征,张才全,汤为学.TSG101-siRNA对肝癌耐药细胞株QGY/CDDP的逆转作用[J].陆军军医大学学报(原第三军医大学学报),2008,30(02):170.
 XIANG Zheng,ZHANG Cai-quan,TANG Wei-xue.Effect of tumor susceptibitity gene 101-siRNA eukaryotic expression vector and cisplatin on proliferation of QGY/CDDP[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(16):170.
[4]郑继军,王阁,邓婧,等.PD98059对肝癌HepG2细胞Tec信号转导作用的初步研究[J].陆军军医大学学报(原第三军医大学学报),2006,28(02):136.
[5]郑继军,王阁.肝癌粘附转移中相关整合素的作用研究现状[J].陆军军医大学学报(原第三军医大学学报),2006,28(02):176.
[6]张百红,贺佳,朱德增,等.一个新的肝癌分期系统的构建[J].陆军军医大学学报(原第三军医大学学报),2006,28(03):253.
[7]李宁,候丽娟.自体CIK细胞治疗肝癌患者的护理[J].陆军军医大学学报(原第三军医大学学报),2006,28(05):485.
[8]戴纪刚,肖颖彬,闵家新,等.高低转移小鼠肝癌细胞线粒体DNA遗传变异的研究[J].陆军军医大学学报(原第三军医大学学报),2006,28(20):2030.
[9]张汝钢,房殿春.对TRAIL耐药的肝癌细胞caspase-8基因甲基化状态及其mRNA表达[J].陆军军医大学学报(原第三军医大学学报),2006,28(12):1273.
[10]王振军,李辛.7例肝癌介入治疗后肝破裂的诊治体会[J].陆军军医大学学报(原第三军医大学学报),2006,28(12):1319.
[11]金世龙,余天雾,黄中荣,等.As2O3在HuH7及CD13+CD133+LCSCs增殖和分化中作用的初步观察[J].陆军军医大学学报(原第三军医大学学报),2012,34(18):1857.
 Jin Shilong,Yu Tianwu,Huang Zhongrong,et al.Role of arsenic trioxide in proliferation of HuH7 cells and differentiation of CD13+CD133+ LCSCs[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(16):1857.

更新日期/Last Update: 2012-07-30